Nucresiran

RNA / oligonucleotide

Phase 3underway

Evidence outlook · registrational

Transthyretin Amyloidosis with Polyneuropathy: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-12-27.

Also in development:Transthyretin Amyloidosis with Cardiomyopathy · Phase 3

Featured evidence outside this drug's tracked markets:NCT05661916 · Healthy Volunteers · Phase 1 · completed · ungraded

Company guidance: data expected by 2030 (Alnylam Pharmaceuticals, 29 Oct 2026). “We continue to expect to launch nucresiran in ATTR-CM by 2030, assuming positive data and regulatory approval.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Transthyretin Amyloidosis with Cardiomyopathy
Transthyretin Amyloidosis with Polyneuropathy
Phase 1 (1)
Other / comorbidity
NCT05661916 · Alnylam Pharmaceuticals
2023-01-16 – 2025-09-30 · Transthyretin-Mediated Amyloidosis
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, 5 of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nucresiran: this drugPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Acoramidis (Attruby)ApprovedSmall moleculeTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162
CliramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Eplontersen (Wainua)Phase 3RNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed
Nexiguran ZiclumeranPhase 3Gene therapy / editingTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nucresiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 3Transthyretin Amyloidosis with PolyneuropathyRecruiting
Est. primary completion 2027-12-27 · NCT07223203 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Phase 3Transthyretin Amyloidosis with CardiomyopathyRecruiting
Est. primary completion 2030-05-28 · NCT07052903 · CT.gov ↗
What to watch

See the full readout calendar ↗